{
    "name": "miltefosine",
    "comment": "Rx",
    "other_names": [
        "Impavido"
    ],
    "classes": [
        "Antileishmaniasis Agents"
    ],
    "source": "https://reference.medscape.com/drug/impavido-miltefosine-999893",
    "pregnancy": {
        "common": [
            "There is pregnancy exposure registry that monitors pregnancy outcomes in women exposed to IMPAVIDO during pregnancy; Healthcare providers are encouraged to register patients by calling 1-866-588-5405 or vising online at ",
            "Contraindicated during pregnancy; based on data from animal reproduction studies, therapy may cause embryo-fetal toxicity when administered to pregnant women; there are no available data on use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal and/or fetal outcomes",
            "If a woman becomes pregnant while being treated, treatment should be discontinued and the patient counseled about potential risk to the fetus",
            "Embryo-fetal toxicity, including death and fetal malformations, was observed in embryo-fetal studies in rats and rabbits administered oral miltefosine during organogenesis at doses that were respectively 0.06 and 0.2 times the maximum recommended human dose (MRHD) of 3.33 mg/kg/day",
            "Numerous visceral and skeletal fetal malformations were observed in a fertility study in female rats administered miltefosine prior to mating through day 7 of pregnancy at doses 0.3 times the MRHD",
            "Verify pregnancy status prior to initiating therapy in females of reproductive potential",
            "Advise females of reproductive potential to use effective contraception during treatment and for 5 months after last dose",
            "Vomiting and/or diarrhea occurring during therapy may affect absorption of oral contraceptives and therefore compromise their efficacy",
            "If vomiting and/or diarrhea occur during therapy, advise females to use an additional non-oral method of effective contraception"
        ],
        "specific": [
            {
                "type": "Infertility",
                "description": [
                    "  ",
                    "  ",
                    "Based on animal fertility studies, therapy may impair fertility in females of reproductive potential",
                    "The effects of therapy on human female fertility have not been formally studied",
                    "  ",
                    "  ",
                    "Based on animal fertility and postmarketing studies, therapy may impair fertility in males of reproductive potential",
                    "In an open-label, uncontrolled, single-center study that assessed the effects of the drug on sperm parameters; treatment was associated with reductions in all sperm parameters at the end of treatment; all sperm parameters, except for sperm concentration, recovered on follow-up assessments at 3 and 6 months after treatment completion; for sperm concentration, small mean decreases persisted on follow-up assessments at 3 and 6 months after treatment completion",
                    "No clinically meaningful changes were observed in serum testosterone or FSH concentrations",
                    "Reductions in ejaculate volume and temporary absence of ejaculate were reported in an observational study of male patients who received the therapy; these adverse reactions resolved in all patients in this study upon completion of therapy",
                    "The effect of therapy on spermatogenesis may persist for an unknown duration; whether therapy affects male fertility is unknown"
                ]
            }
        ]
    },
    "lactation": {
        "common": [
            "There are no data on presence of miltefosine in human or animal milk, the effects on breastfed infants or on milk production; because of the potential for serious adverse reactions, breastfeeding is not recommended during treatment and for 5 months after last dose"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Do not administer to pregnant women; may cause fetal harm",
                "Fetal death and teratogenicity occurred in animals administered at doses lower than the recommended human dose",
                "Obtain a serum or urine pregnancy test in females of reproductive potential prior to prescribing",
                "Advise females of reproductive potential to use effective contraception during therapy and for 5 months after therapy"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Pregnancy (see Black Box Warnings)",
                "Sj√ñgren-Larsson syndrome",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "May cause fetal harm; do not use during pregnancy or become pregnancy within 5 months following therapy completion (see Black Box Warnings)",
                "Causes impaired fertility in rats and reversible follicular atresia and diestrus in dogs; reduced viable sperm counts and impaired fertility in rats; effects on human fertility have not been studied",
                "Vomiting and/or diarrhea commonly occur; encourage fluid intake to avoid volume depletion",
                "Vomiting and/or diarrhea occurring during therapy may affect oral contraceptive absorption and thereby compromise their efficacy; advise females to use additional nonhormonal or alternative method(s) of effective contraception",
                "Increased serum creatinine, ALT, AST, bilirubin reported; monitor",
                "Thrombocytopenia reported; monitor platelets",
                "Stevens-Johnson syndrome reported; discontinue if an exfoliative or bullous rash occurs"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Increased transaminases",
            "percent": "3"
        },
        {
            "name": "x ULN",
            "percent": "94"
        },
        {
            "name": "Decreased platelets",
            "percent": "150,000"
        },
        {
            "name": "Vomiting",
            "percent": "62"
        },
        {
            "name": "Decreased appetite",
            "percent": "37.8"
        },
        {
            "name": "Diarrhea",
            "percent": "23.1"
        },
        {
            "name": "Nausea",
            "percent": "20.4"
        },
        {
            "name": "Motion sickness",
            "percent": "35.9-41.7"
        },
        {
            "name": "Headache",
            "percent": "29.2"
        },
        {
            "name": "Vomiting",
            "percent": "28.1"
        },
        {
            "name": "Increased serum creatinine",
            "percent": "4.5-27.5"
        },
        {
            "name": "x baseline",
            "percent": "1.5-3"
        },
        {
            "name": "Diarrhea",
            "percent": "25"
        },
        {
            "name": "Dizziness",
            "percent": "15"
        },
        {
            "name": "Abdominal pain",
            "percent": "4.5-12.5"
        },
        {
            "name": "Decreased appetite",
            "percent": "7.5-11.2"
        },
        {
            "name": "Increased serum creatinine",
            "percent": "10.8"
        },
        {
            "name": "x baseline",
            "percent": "1.5"
        },
        {
            "name": "Asthenia",
            "percent": "10"
        },
        {
            "name": "Increased transaminases",
            "percent": "6.3"
        },
        {
            "name": "x ULN",
            "percent": "3-5"
        },
        {
            "name": "Decreased platelets",
            "percent": "6"
        },
        {
            "name": "Diarrhea",
            "percent": "50,000"
        },
        {
            "name": "Lymphangitis",
            "percent": "2.4"
        },
        {
            "name": "Pyrexia",
            "percent": "7.9"
        },
        {
            "name": "Pruritus",
            "percent": "5.8"
        },
        {
            "name": "Malaise",
            "percent": "5.6"
        },
        {
            "name": "Somnolence",
            "percent": "4.5-5.8"
        }
    ]
}